EBS · Healthcare
EMERGENT BIOSOLUTIONS INC
Smart-money confidence
· 1 of 3 sources firing
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
20
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in EMERGENT BIOSOLUTIONS INC? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$375M
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Exchange
NYSE
About EMERGENT BIOSOLUTIONS INC
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic…
Who's behind the signal
Every informed buyer we can see on EBS, across all three feeds.
Hedge funds · 4
D.E. Shaw & Co
Increased +125%
Millennium Management (Englander)
Increased +205%
Citadel Advisors
Decreased −32%
AQR Capital Management
Decreased −18%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trade history · 11
Every disclosed buy & sell on record — STOCK Act filings
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2021-11-05 | Josh Gottheimer · D-NJ | House | SOLD | $1,001 - $15,000 |
| 2021-10-18 | Josh Gottheimer · D-NJ | House | BOUGHT | $1,001 - $15,000 |
| 2021-09-15 | Josh Gottheimer · D-NJ | House | SOLD | $1,001 - $15,000 |
| 2021-02-23 | Josh Gottheimer · D-NJ | House | SOLD | $1,001 - $15,000 |
| 2020-11-24 | Gilbert Ray Cisneros, Jr. · D-CA | House | BOUGHT | $1,001 - $15,000 |
| 2020-07-30 | Gilbert Ray Cisneros, Jr. · D-CA | House | BOUGHT | $1,001 - $15,000 |
| 2020-06-30 | Gilbert Ray Cisneros, Jr. · D-CA | House | BOUGHT | $1,001 - $15,000 |
| 2020-06-26 | Josh Gottheimer · D-NJ | House | BOUGHT | $1,001 - $15,000 |
| 2020-06-19 | Gilbert Ray Cisneros, Jr. · D-CA | House | BOUGHT | $1,001 - $15,000 |
| 2020-06-15 | Josh Gottheimer · D-NJ | House | BOUGHT | $1,001 - $15,000 |
| 2020-03-26 | Steve Cohen · D-TN | House | SOLD | $1,001 - $15,000 |
Not a model pick — but on our radar.
EMERGENT BIOSOLUTIONS INC isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
0
New positions
2
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+125%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+205%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−32%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−18%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to EMERGENT BIOSOLUTIONS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell EMERGENT BIOSOLUTIONS INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime